These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 3-amino-4-sulfonylpyridinone acetamide and related pyridothiadiazine thrombin inhibitors. Sanderson PE; Cutrona KJ; Savage KL; Naylor-Olsen AM; Bickel DJ; Bohn DL; Clayton FC; Krueger JA; Lewis SD; Lucas BJ; Lyle EA; Wallace AA; Welsh DC; Yan Y Bioorg Med Chem Lett; 2003 Apr; 13(8):1441-4. PubMed ID: 12668008 [TBL] [Abstract][Full Text] [Related]
5. 2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors. Lee L; Kreutter KD; Pan W; Crysler C; Spurlino J; Player MR; Tomczuk B; Lu T Bioorg Med Chem Lett; 2007 Nov; 17(22):6266-9. PubMed ID: 17889527 [TBL] [Abstract][Full Text] [Related]
6. Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. Kreutter KD; Lu T; Lee L; Giardino EC; Patel S; Huang H; Xu G; Fitzgerald M; Haertlein BJ; Mohan V; Crysler C; Eisennagel S; Dasgupta M; McMillan M; Spurlino JC; Huebert ND; Maryanoff BE; Tomczuk BE; Damiano BP; Player MR Bioorg Med Chem Lett; 2008 May; 18(9):2865-70. PubMed ID: 18420408 [TBL] [Abstract][Full Text] [Related]
7. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors. Leblond L; Grouix B; Boudreau C; Yang Q; Siddiqui MA; Winocour PD Thromb Res; 2000 Nov; 100(3):195-209. PubMed ID: 11108907 [TBL] [Abstract][Full Text] [Related]
9. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. Burgey CS; Robinson KA; Lyle TA; Sanderson PE; Lewis SD; Lucas BJ; Krueger JA; Singh R; Miller-Stein C; White RB; Wong B; Lyle EA; Williams PD; Coburn CA; Dorsey BD; Barrow JC; Stranieri MT; Holahan MA; Sitko GR; Cook JJ; McMasters DR; McDonough CM; Sanders WM; Wallace AA; Clayton FC; Bohn D; Leonard YM; Detwiler TJ; Lynch JJ; Yan Y; Chen Z; Kuo L; Gardell SJ; Shafer JA; Vacca JP J Med Chem; 2003 Feb; 46(4):461-73. PubMed ID: 12570369 [TBL] [Abstract][Full Text] [Related]
11. Efforts toward oral bioavailability in factor VIIa inhibitors. Vijaykumar D; Rai R; Shaghafi M; Ton T; Torkelson S; Leahy EM; Riggs JR; Hu H; Sprengeler PA; Shrader WD; O'Bryan C; Cabuslay R; Sanford E; Gjerstadt E; Liu L; Sukbuntherng J; Young WB Bioorg Med Chem Lett; 2006 Jul; 16(14):3829-32. PubMed ID: 16650987 [TBL] [Abstract][Full Text] [Related]
12. 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors. Rewinkel JB; Lucas H; van Galen PJ; Noach AB; van Dinther TG; Rood AM; Jenneboer AJ; van Boeckel CA Bioorg Med Chem Lett; 1999 Mar; 9(5):685-90. PubMed ID: 10201829 [TBL] [Abstract][Full Text] [Related]
13. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles. Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642 [TBL] [Abstract][Full Text] [Related]
14. Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664. Das J; Kimball SD; Hall SE; Han WC; Iwanowicz E; Lin J; Moquin RV; Reid JA; Sack JS; Malley MF; Chang CY; Chong S; Wang-Iverson DB; Roberts DG; Seiler SM; Schumacher WA; Ogletree ML Bioorg Med Chem Lett; 2002 Jan; 12(1):45-9. PubMed ID: 11738570 [TBL] [Abstract][Full Text] [Related]
15. Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy. Tucker TJ; Lumma WC; Lewis SD; Gardell SJ; Lucas BJ; Baskin EP; Woltmann R; Lynch JJ; Lyle EA; Appleby SD; Chen IW; Dancheck KB; Vacca JP J Med Chem; 1997 May; 40(11):1565-9. PubMed ID: 9171866 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides. Burgey CS; Robinson KA; Lyle TA; Nantermet PG; Selnick HG; Isaacs RC; Lewis SD; Lucas BJ; Krueger JA; Singh R; Miller-Stein C; White RB; Wong B; Lyle EA; Stranieri MT; Cook JJ; McMasters DR; Pellicore JM; Pal S; Wallace AA; Clayton FC; Bohn D; Welsh DC; Lynch JJ; Yan Y; Chen Z; Kuo L; Gardell SJ; Shafer JA; Vacca JP Bioorg Med Chem Lett; 2003 Apr; 13(7):1353-7. PubMed ID: 12657281 [TBL] [Abstract][Full Text] [Related]
17. P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position. Isaacs RC; Newton CL; Cutrona KJ; Mercer SP; Dorsey BD; McDonough CM; Cook JJ; Krueger JA; Lewis SD; Lucas BJ; Lyle EA; Lynch JJ; Miller-Stein C; Michener MT; Wallace AA; White RB; Wong BK Bioorg Med Chem Lett; 2011 Mar; 21(5):1532-5. PubMed ID: 21295466 [TBL] [Abstract][Full Text] [Related]
18. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. Dragovich PS; Prins TJ; Zhou R; Brown EL; Maldonado FC; Fuhrman SA; Zalman LS; Tuntland T; Lee CA; Patick AK; Matthews DA; Hendrickson TF; Kosa MB; Liu B; Batugo MR; Gleeson JP; Sakata SK; Chen L; Guzman MC; Meador JW; Ferre RA; Worland ST J Med Chem; 2002 Apr; 45(8):1607-23. PubMed ID: 11931615 [TBL] [Abstract][Full Text] [Related]
20. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. Lu T; Markotan T; Coppo F; Tomczuk B; Crysler C; Eisennagel S; Spurlino J; Gremminger L; Soll RM; Giardino EC; Bone R Bioorg Med Chem Lett; 2004 Jul; 14(14):3727-31. PubMed ID: 15203151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]